Says FY25 sales expected to grow high single digits, unchanged from its prior view, while core operating income is expected to grow low teens, up from prior guidance of low double-digits.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVS:
- Novartis announces CFO Kirsch to retire, Mehta to succeed
- NVS Earnings: NVS Stock Flattens Despite Sales Surge and $10B Buyback Plan
- Novartis: Strong Performance and Strategic Initiatives Justify Buy Rating
- NVS Earnings: NVS Stock Flatlines Despite Healthier Q2 Sales
- Is NVS Stock (NVS) a Buy Ahead of Q2 Earnings?